Investigating a new treatment for Alzheimer's disease using mixed receptor modulators
Dopamine and Sigma Receptor Mixed Modulators for the Treatment of Alzheimer's Disease
This study is looking at a new treatment for Alzheimer's disease using a small molecule called AM73, which might help improve brain function and behavior in mice, with hopes that it could lead to better options for people living with Alzheimer's.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Southern Illinois Univ at Edwardsville NIH-funded |
| Lab location | 1 site (Edwardsville, United States) |
| Project ID | NIH-11101297 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for Alzheimer's disease (AD) by exploring a small molecule called AM73 that targets specific brain receptors involved in cognitive decline. The study will evaluate the effects of chronic treatment with AM73 in a mouse model, assessing its impact on behavior and brain function. By analyzing changes in key brain regions associated with AD, the research aims to provide insights into how this novel approach could improve symptoms of the disease. The findings could lead to new therapeutic options for patients suffering from Alzheimer's.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 65 and older who are experiencing cognitive decline or have been diagnosed with Alzheimer's disease.
Not a fit: Patients under the age of 65 or those without cognitive decline or Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that improves cognitive function and quality of life for Alzheimer's patients.
How similar studies have performed: While the approach of using mixed receptor modulators is novel, similar studies targeting brain receptors have shown promise in other neurological conditions.
Where this research is happening
Edwardsville, United States
- Southern Illinois Univ at Edwardsville — Edwardsville, United States (Active)
Researchers
- Principal investigator: Witt, Ken a — Southern Illinois Univ at Edwardsville
- Study coordinator: Witt, Ken a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.